By Connor Hart
A drug that targets an underlying cause of Alzheimer's disease being commercialized by Eisai and Biogen has received marketing approval from the European Commission.
The companies said Tuesday that the approval makes the therapy, lecanemab, the first of its kind to be granted a marketing approval in the European Union. The approval applies to all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
Lecanemab is indicated to treat certain adult patients with mild cognitive impairment and dementia due to Alzheimer's disease, the company said.
"The approval of lecanemab by the European Commission marks the thirteenth approval of this important medicine, which has already benefited thousands of patients in the United States, Japan and other regions of the world," Biogen Chief Executive Christopher Viehbacher said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 15, 2025 19:57 ET (23:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.